Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Vaccine ; 33(6): 819-25, 2015 Feb 04.
Article in English | MEDLINE | ID: mdl-25500307

ABSTRACT

BACKGROUND: Polio eradication remains a challenge in Pakistan and the causes for the failure to eradicate poliomyelitis are complex. Undernutrition and micronutrient deficiencies, especially zinc deficiency, are major public health problems in Pakistan and could potentially affect the response to enteric vaccines, including oral poliovirus vaccine (OPV). OBJECTIVE: To assess the impact of zinc supplementation among infants on immune response to oral poliovirus vaccine (OPV). METHODS: A double-blind, randomized placebo-controlled trial was conducted in newborns (aged 0-14 days). Subjects were assigned to either receive 10mg of zinc or placebo supplementation daily for 18 weeks. Both groups received OPV doses at birth, at 6 weeks, 10 weeks and 14 weeks. Data was collected on prior immunization status, diarrheal episodes, breastfeeding practices and anthropometric measurements at recruitment and at 6 and 18 weeks. Blood samples were similarly collected to determine the antibody response to OPV and for micronutrient analysis. Logistic regression was used to determine the relationship between seroconversion and zinc status. RESULTS: Overall, 404 subjects were recruited. At recruitment, seropositivity was already high for poliovirus (PV) serotype 1 (zinc: 91.1%; control: 90.5%) and PV2 (90.0%; 92.7%), with lower estimates for PV3 (70.0%; 64.8%). By week 18, the proportion of subjects with measured zinc levels in the normal range (i.e. ≥60 µg/dL) was significantly greater in the intervention group compared to the control group (71.9%; 27.4%; p<0.001). No significant difference in seroconversion was demonstrated between the groups for PV1, PV2, or PV3. CONCLUSIONS: There was no effect of zinc supplementation on OPV immunogenicity. These conclusions were confirmed when restricting the analysis to those with measured higher zinc levels.


Subject(s)
Antibodies, Viral/blood , Dietary Supplements , Poliomyelitis/prevention & control , Poliovirus Vaccine, Oral/administration & dosage , Zinc/administration & dosage , Double-Blind Method , Drug Administration Schedule , Female , Humans , Infant , Infant, Newborn , Logistic Models , Male , Pakistan , Poliomyelitis/blood , Poliomyelitis/immunology , Poliovirus/immunology , Poliovirus Vaccine, Oral/immunology , Vaccination
2.
Vaccine ; 31(15): 1987-93, 2013 Apr 08.
Article in English | MEDLINE | ID: mdl-23429005

ABSTRACT

BACKGROUND: Seroprevalence studies provide important data on performance of immunization programs, susceptible groups and populations at-risk of future outbreaks. Identifying risk factors that affect seroconversion of the oral polio vaccine (OPV) will enable the polio eradication initiatives to increase seroprevalence. This paper describes the first population-based seroprevalence survey in Pakistan. METHODS: This study evaluated the seroprevalence of poliovirus (PV) types 1, 2, and 3 antibodies to OPV in an illustrative sample of 554 subjects 6-11 months of age in three geographic locations of Pakistan (Lahore, Karachi, and Peshawar) representing a low socioeconomic at-risk populations. Antibody titers were measured and sero protection rates and geometric median titers were compared among different geographic regions and populations, as were demographics and OPV vaccination history collected by questionnaire. Univariate and multivariate analyses were conducted on subject characteristics to assess for potential risk factors for failure to sero-convert. RESULTS: The average seroprevalence of PV1, PV2, and PV3 was 96.0%, 87.9% and 86.7%, respectively. The lowest sero protection rate for all three serotypes was for Karachi with 90.2%, 73.8%, and 78.8% for PV1, PV2, and PV3, respectively. Significant regional variation in PV3 seroprevalence was found (range: 74.2-100%). In the univariate analysis, age, total and campaign OPV doses were associated with higher seroprevalence, whereas stunting, respondent education and diarrhea in the past six months were significant risk factors for failure to sero-convert. CONCLUSIONS: These findings demonstrate consistently high levels of antibody response to PV1 and more geographically varied response to PV2 and PV3. Additionally, important risk factors affecting seropositivity were identified.


Subject(s)
Antibodies, Viral/blood , Antibodies, Viral/immunology , Immunization Programs , Poliomyelitis/epidemiology , Poliomyelitis/immunology , Poliovirus/immunology , Antibody Formation/immunology , Diarrhea/epidemiology , Diarrhea/immunology , Disease Eradication/methods , Disease Outbreaks/prevention & control , Educational Status , Female , Humans , Immunization Programs/statistics & numerical data , Infant , Male , Pakistan/epidemiology , Poliomyelitis/prevention & control , Poliomyelitis/virology , Poliovirus Vaccine, Oral/administration & dosage , Poliovirus Vaccine, Oral/immunology , Risk Assessment , Risk Factors , Seroepidemiologic Studies , Socioeconomic Factors , Surveys and Questionnaires , Vaccination/statistics & numerical data
SELECTION OF CITATIONS
SEARCH DETAIL
...